Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
Get Alerts INSM Hot Sheet
Join SI Premium – FREE
This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30 days following the conclusion of this live event.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Vice President, Investor Relations
(646) 812-4030
[email protected]
Media:
Vice President, Corporate Communications
(862) 842-6819
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-2026-goldman-sachs-annual-global-healthcare-conference-302782306.html
SOURCE Insmed Incorporated
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TTW Highlights Top 100 Luxury Hotels in the World for 2026
- What To Expect At DEA Rescheduling Hearing: When Does Marijuana Become Medicine? The Answer Is Proof
- Drive Point Exchange Announces Strategic Partnership with Apex Auto Solutions, NAAC, and Insurify.com
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share